Bristol-Myers Squibb Company announced effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President, Research and Early Development, has decided to leave the company. In connection with his departure, Dr. Vessey will be entitled to (i) severance benefits in accordance with the company's Senior Executive Severance Plan, and (ii) (A) pro-rated vesting of Market Share Units (MSUs) and Performance Share Units (PSUs) and (B) full vesting of his 2019 Restricted Stock Units Inducement Award, in each case, in accordance with the company's equity award agreements under the company's 2012 and 2021 Stock Award and Incentive Plans.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.06 USD | -0.96% |
|
-5.74% | -21.93% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.93% | 82B | |
+54.07% | 816B | |
+38.59% | 634B | |
-7.05% | 351B | |
+15.44% | 323B | |
+5.72% | 293B | |
+13.40% | 238B | |
+0.61% | 222B | |
+13.24% | 218B | |
+7.42% | 167B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Company Announces Resignation of Dr. Rupert Vessey, Executive Vice President, Research and Early Development, Effective July 3, 2023